Gemfibrozil Tablet
Product Images NDC 66267-436

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 66267-436). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

66267 436 30

This is a description of a medication, specifically Gemfibrozil 600mg. The tablets are white and capsule-shaped with a score on one side and "225" on the other. The product is manufactured by NuCare Pharmaceuticals with NDC 66267-436-30 and each tablet contains 600mg of Gemfibrozil, USP. The lot number is provided: 000000. The medication may have side effects, but should be stored at a controlled temperature of 68-77°F.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 01)

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 02)

The table shows the reduction in Coronary Heart Disease rates per 1000 patients based on baseline lipids in the Helsinki Heart Study over a 52-year period. The lipid values at baseline were measured in mg/dL. The study was conducted with a placebo group and a group taking gemfibrozil tablets. The incidence of events included fatal and non-fatal myocardial infarctions plus sudden cardiac deaths. The table also shows differences in rates between the placebo and gemfibrozil groups.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 03)

This is a table showing the occurrence of cardiac events and all-cause mortality during a 3.5-year open-label follow-up to the Helsinki Heart Study. The table consists of six groups of patients designated by original randomization and drug taken during the follow-up period. The number of patients in each group is listed (ranging from 215 to 1207). The number of cardiac events and all-cause mortality events are also displayed in each group. No further information is available.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 04)

This is a table presenting the results of the Helsinki Heart Study. The table reports the number of cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality for patients taking gemfibrozil versus placebo. The table shows hazard ratios and confidence intervals for each of these events. The intention-to-treat analysis was used, including only patients originally randomized and ignoring open treatment switches and exposure to study conditions. The study lasted for 8.5 years and included both fatal and non-fatal myocardial infarctions plus sudden cardiac deaths.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 05)

This text appears to be a list of potential side effects of a medication. It includes medical conditions such as weight loss, cardiac irregularities, jaundice, confusion, impotence, and muscle pain, as well as laboratory results such as increased liver enzymes and decreased blood cell count. The text also notes that a causal relationship has not been established for these potential side effects.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.